# Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction

> **NCT05139472** · PHASE4 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 8 (actual)

## Conditions studied

- Heart Failure with Preserved Ejection Fraction
- Heart Failure, Diastolic
- Diabetes Mellitus

## Interventions

- **DRUG:** Empagliflozin 10 MG

## Key facts

- **NCT ID:** NCT05139472
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-09
- **Primary completion:** 2023-09-20
- **Final completion:** 2024-02-19
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05139472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05139472, "Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05139472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*